Core Insights - The company has received a new patent for its LIBERTY Endovascular Robotic System, bringing its total to 12 granted patents globally and 57 pending applications, which enhances its intellectual property portfolio [1][2] - The new patent allows for modular capabilities in the robotic system, potentially expanding its application to a wider range of endovascular procedures, thereby increasing the Total Addressable Market (TAM) [1][2] - The company aims to address over 6 million annual endovascular procedures in the U.S., significantly higher than the current estimate of 2.5 million procedures [2][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [4] - The company has developed the first single-use, fully disposable endovascular robotic system, which aims to remove traditional barriers to accessing advanced robotic systems [4]

Core Insights - Microbot Medical Inc. has received a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority to enhance its manufacturing capabilities for the LIBERTY® Endovascular Robotic System, pending FDA marketing clearance [1][2][3] Group 1: Company Developments - The grant is expected to strengthen the company's balance sheet and operational readiness as it awaits FDA's decision on marketing clearance [3] - The Israel Innovation Authority recognized the company's recent achievements, the target market's size, the competitive advantages of a single-use robot, and the expected benefits to healthcare systems [2] - The LIBERTY® System is an investigational device currently pending FDA 510(k) clearance and is not available for sale in the U.S. [3][4] Group 2: Market Positioning - Microbot Medical aims to redefine endovascular robotics and improve care quality for patients globally with its single-use, fully disposable robotic system [4] - The company believes the grant validates its technology and reflects the IIA's confidence in its ability to scale manufacturing and meet business objectives [2][3]

Core Insights - Microbot Medical Inc. has appointed Christina Bailey as the new Vice President of Sales, bringing 20 years of medical device sales experience and a successful track record in leading commercial teams [1][2][3] - The company is preparing for the anticipated launch of its LIBERTY Endovascular Robotic System, which is currently pending FDA 510(k) clearance and not available for sale in the U.S. [3][4] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to enhance patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system aimed at overcoming traditional barriers to advanced robotic systems [4] Leadership and Experience - Christina Bailey has held various sales leadership roles at notable companies such as Boston Scientific, Abbott, Stryker, and Intuitive Surgical, equipping her with insights to drive growth and innovation [2] - Her previous role as Vice President of US Sales at Endologix involved building and scaling sales teams and achieving significant sales milestones [2]

Core Insights - Microbot Medical Inc. is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, highlighting the growth and innovation in the endovascular robotics field driven by market demand [1][3] - The session will feature discussions on emerging technologies in the peripheral vascular, neurovascular, and cardiovascular spaces, with a focus on educating the medical community about the LIBERTY Endovascular Robotic System [2][3] - The SRS aims to foster education and collaboration in robotic surgery, providing opportunities for multi-centric studies and training for young professionals in the field [4] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [6] - The company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to remove barriers to accessing advanced robotic systems [6] - The LIBERTY system is currently pending FDA 510(k) clearance and is not available for sale in the U.S. as the company strengthens its sales and marketing infrastructure for its launch [5]

Core Insights - Microbot Medical Inc. has been added to the Russell Microcap Index, effective June 30, 2025, enhancing its visibility in the market [1][2] - The inclusion reflects the company's strong execution and momentum, particularly in relation to its LIBERTY Endovascular Robotic System and ongoing FDA interactions [2] - The Russell US Indexes reconstitution captures the 4,000 largest US stocks, and membership in the Russell Microcap Index ensures automatic inclusion in relevant growth and value style indexes [2][3] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [4] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3]

Core Insights - Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global intellectual property expansion strategy [1] - The company currently holds nine patents globally and has 59 pending patent applications, which helps maintain a competitive advantage and protect the unique capabilities of the LIBERTY System [2] - Preparations for the anticipated U.S. launch of the LIBERTY System are underway, with regulatory, operational, and commercial activities accelerating [3] - The company aims to impact both developed and emerging markets, with an estimated 2 million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China [4] - Microbot Medical is focused on redefining endovascular robotics and improving patient care through its innovative, single-use, fully disposable robotic system [5]

Core Insights - Microbot Medical Inc. is expanding its commercial team in anticipation of the U.S. launch of the LIBERTY Endovascular Robotic System, projected for the third quarter of 2025 [1][2] - The company is actively engaged with the FDA, expecting a 510(k) decision during the third quarter of this year, which aligns with the FDA's original review timeline [1][4] - The addition of Michael Lytle as the head of Sales Operations & Analytics is aimed at enhancing sales infrastructure and optimizing the sales cycle [2][3] Company Developments - The LIBERTY System is currently under FDA review and is not available for sale in the U.S. until clearance is granted [4] - Michael Lytle's previous experience at ZOLL Cardiac Management Solutions is expected to contribute to the company's market targeting and resource allocation [3] - The company aims to redefine endovascular robotics and improve patient care through its innovative, single-use, fully disposable robotic system [5]

Core Insights - Microbot Medical Inc. has strengthened its U.S. commercial leadership team with the addition of a new Vice President of Marketing and a Director of Human Resources, preparing for the launch of its LIBERTY® Endovascular Robotic System [1][4][6] - Positive data from a pivotal study has increased confidence in the market reception of LIBERTY® [1] Leadership Additions - Allison Rosefort has been appointed as Vice President of Marketing, bringing over 15 years of experience in healthcare marketing and a proven track record of driving double-digit revenue growth [2][3] - Lisa Dobbins has joined as Director of Human Resources, with a background in building high-performing teams in the MedTech sector [4][5] Commercialization Strategy - The company aims to be ready for the immediate launch of LIBERTY® following FDA clearance, reflecting its commitment to establishing a robust commercial infrastructure [6] - The recent hiring of Paul Mullen as Vice President of Sales complements the new marketing and HR leadership, enhancing the company's commercialization readiness [1][6] Product Overview - LIBERTY® is an investigational device pending FDA 510(k) clearance and is not currently available for sale in the U.S. [6] - The device is designed to redefine endovascular robotics and improve patient care globally [7]

Core Insights - The LIBERTY® Endovascular Robotic System demonstrated successful robotic navigation in all cases, achieving a 100% success rate and meeting the primary endpoint of the ACCESS-PVI pivotal trial [1][8] - The system resulted in a 92% reduction in radiation exposure with no adverse device events reported, indicating its safety and efficacy [1][2][8] - The study was conducted at three leading medical centers in the U.S., showcasing the credibility of the results [1] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to enhance patient care globally [5] - The company has developed the first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers in accessing advanced robotic systems [5] Clinical Study Highlights - The ACCESS-PVI study involved 20 cases, with a mean robotic navigation time to target of 3 minutes [8] - Participating physicians reported a 100% satisfaction rate with the performance of the LIBERTY® system [8] - The mean difference in radiation exposure between the operator and control was a reduction of 29.8 µS, confirming the system's effectiveness in minimizing radiation [8] Future Outlook - The company is preparing for the commercial launch of LIBERTY® and is confident in its market reception based on positive clinical data and feedback from investigators [4] - LIBERTY® is currently pending FDA 510(k) clearance and is not available for sale in the U.S. [4]